

Iron Skin Staining: A Rare but Permanent Complication Following IV Iron Infusion

Hiperpigmentação Cutânea por Deposição de Ferro: Uma Complicação Rara, mas Permanente Após Administração Intravenosa de Ferro

Tiago DIAS DA COSTA^{1,2}, António MATEUS-PINHEIRO^{1,2}, Sónia MOREIRA^{1,2,3}
Acta Med Port 2025 Jan;38(1):52-53 • <https://doi.org/10.20344/amp.22136>

Keywords: Extravasation of Diagnostic and Therapeutic Materials; Ferric Compounds/adverse effects; Iron/adverse effects; Skin Pigmentation/drug effects

Palavras-chave: Compostos Férricos/efeitos adversos; Extravasamento de Materiais Terapêuticos e Diagnósticos; Ferro/efeitos adversos; Pigmentação da Pele/efeitos dos fármacos



Figure 1 – Iron skin staining after ferric carboxymaltose infusion: immediately after the infusion, diffuse erythema and edema were observed in the infusion region and surrounding areas (A). Iron staining showing a brownish colour persistent after six months: changes evolved over the following days into a generalized hyperpigmentation of that area, with relatively well-defined edges, along with resolution of the associated edema (B).

A 68-year-old female patient presented to the emergency department with dyspnea and asthenia. She had a history of heart failure induced by drug cardiotoxicity (trastuzumab). On physical examination, she displayed peripheral edema and jugular venous distension. Bloodwork revealed

elevated levels of NT-proBNP (16568 pg/mL), decreased hemoglobin (10.8 g/dL), serum ferritin (41 µg/dL), and transferrin saturation (18%). We treated the patient with intravenous diuretics, levosimendan, and ferric carboxymaltose perfusion. The latter caused diffuse erythema with edema at

1. Internal Medicine Department. Unidade Local de Saúde de Coimbra. Coimbra. Portugal.
 2. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal.
 3. European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN). Coimbra. Portugal.
- ✉ **Autor correspondente:** Tiago Dias da Costa. tiagodcsilva@hotmail.com

Recebido/Received: 31/07/2024 - **Aceite/Accepted:** 02/10/2024 - **Publicado Online/Published Online:** 18/11/2024 - **Publicado/Published:** 02/01/2025
Copyright © Ordem dos Médicos 2025



the injection site (Fig. 1A), which was suggestive of iron skin staining (ISS), characterized by persistent hyperpigmentation (Fig 1B).

Iron skin staining is a rare and potentially irreversible side effect of parenteral iron preparations due to cutaneous and subcutaneous tissue extravasation.¹ The likelihood of ISS can be minimized by strictly following transparent administrative and monitoring protocols, ensuring comprehensive staff training, and offering patient information.^{2,3} Referral to a dermatology clinic for treatment with a nanosecond Q-switched laser or a picosecond laser may allow the hyperpigmentation to be attenuated.

AUTHOR CONTRIBUTIONS

TCS: Conception, design, writing and critical review of the manuscript.

AMP: Conception and writing of the manuscript.

SM: Conception and critical review of the manuscript.

All authors approved the final version to be published.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2024.

REFERENCES

1. Crowley CM, McMahon G, Desmond J, Imcha M. Preventing skin staining: an effective iron infusion protocol. *Int J Health Care Qual Assur.* 2020;33:199-209.
2. Lucas S, Garg M. Intravenous iron: an update. *Intern Med J.* 2024;54:26-

DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients' data publication.

PATIENT CONSENT

Obtained.

COMPETING INTERESTS

SM received payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Alnylam Pharmaceuticals, Bial, BioMarin, Daiichi Sankyo, Mylan, Novartis Farma and Sanofi; received support for attending meetings and/or travel from Alnylam Pharmaceuticals, Bial, BioMarin, Daiichi Sankyo, Mylan, Novartis Farma, and Sanofi; participated in advisory boards sponsored by Alnylam Pharmaceuticals and BioMarin.

All other authors have declared that no competing interests exist.

FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

- 34.
3. Van Doren L, Auerbach M. IV iron formulations and use in adults. *Hematology Am Soc Hematol Educ Program.* 2023;2023:622-9.